Blog

  • Pakistan hikes air cargo handling charges, some rates increase by up to 100 times

    Pakistan hikes air cargo handling charges, some rates increase by up to 100 times

    The Pakistan Airports Authority (PAA) has raised cargo handling charges across all airports in the country, with certain categories seeing increases of up to 100 times, according to an official notification issued early Wednesday.

    This marks the first revision of cargo tariffs in five years. The decision, approved by the PAA’s executive committee, aims to align the charges with the growing operational costs of managing airport services.

    Under the revised tariff schedule, the charge for transporting pet birds has been raised by 50%, from Rs 200 to Rs 300 per kilogram. Similarly, cargo charges on betel leaves, commonly shipped across the country, have been doubled from Rs 35 to Rs 70 per kilogram.

    General cargo rates have also increased by 25%, moving from Rs 100 to Rs 125 per kilogram. The new tariff also includes air freight fees for pets like cats and dogs, along with various other items categorized as general cargo.

    PAA officials defended the hikes, stating that the charges had remained unchanged for the past five years, despite rising service costs at airports.

    The PAA, established as a public sector autonomous body in 2024, is responsible for managing and developing Pakistan’s airports and air transport services.


    Continue Reading

  • Nuclear Energy Agency (NEA) – New version released: The NEA Shielding Integral Benchmark Archive and Database (SINBAD)

    The NEA has released version 2 of the Shielding Integral Benchmark Archive and Database (SINBAD), following the migration to a collaborative development environment and a standardised dataset format. SINBAD, developed since the early 1990s by the NEA and the US Radiation Safety Information Computational Center (RSICC), aims to preserve radiation shielding benchmark experiments for the international community. The SINBAD Task Force, under the NEA Expert Group on Physics of Reactor Systems (EGPRS), now steers its development in collaboration with RSICC.

    The new SINBAD version includes 105 benchmarks for shielding assessments of fission and fusion systems, accelerator shielding and nuclear data evaluations. It represents an internationally recognised resource for validation and verification of radiation transport applications.

    The new SINBAD release is maintained and distributed through the NEA GitLab system provided by the NEA Data Bank, enabling users to give direct feedback and suggest improvements. The SINBAD Task Force manages and evaluates user contributions, following a transparent, version-controlled development process. This development strategy follows successful examples from Open Software development projects, such as the LINUX kernel.

    Organisations from NEA Data Bank member countries can request SINBAD version 2 from the NEA Data Bank, while professionals from non-member countries can request it from RSICC.

    Request SINBAD Version 2 at the NEA Data Bank: SINBAD Version 2, Volumes 1 and 2 (Package NEA-1939).

    Request SINBAD Version 2 at the RSICC: https://rsicc.ornl.gov.

    Continue Reading

  • Dalai Lama confirms he will have a successor after his death

    Dalai Lama confirms he will have a successor after his death

    What has happened in Tibet since the Dalai Lama fled to Indiapublished at 10:20 British Summer Time

    Anbarasan Ethirajan
    South Asia Regional Editor

    Image source, Getty Images
    Image caption,

    A photo of Chinese Communist troops building a bridge across one of Tibet’s rivers to transport forces

    For Tibetans, the Dalai Lama’s departure in 1959 was a
    devastating turning point.

    Thousands died fighting Chinese troops after he fled. The
    Tibetan rebellion was brutally suppressed. Many dissidents were deported to
    mainland China.

    More than 80,000 fled their homeland.

    After the Chinese government established the Tibetan Autonomous
    Region (TAR) in 1965 a large number of Tibet’s monasteries and cultural
    artefacts were destroyed.

    Beijing restored its people’s freedom to practice their religion
    in the 1980s, but monks and nuns often complained of persecution.

    China also began a large-scale immigration of the Han Chinese
    which Beijing argued helped the region economically. But Tibetan leaders said
    it threatened their unique culture.

    In 2008, tensions between Tibetan and Han Chinese communities in
    Lhasa erupted into deadly violence that lasted for several days.

    Dalai LamaImage source, Getty Images
    Image caption,

    Photo taken during a government-organised media tour of a school classroom in Lhasa in China’s Tibet Autonomous Region

    Today, Tibet remains tightly controlled by Chinese authorities.

    According to Human Rights Watch, since 2016 China has dramatically accelerated the relocation of rural villagers and
    herders in Tibet. It says the relocations—often to areas hundreds
    of kilometres away—are voluntary and will “improve people’s livelihood” opportunities.

    Beijing also says the region is one of the fastest growing provincial economies, with fresh
    investments and improved living conditions.

    But critics allege the flow of information from Tibet is tightly controlled.

    Continue Reading

  • Australia says it cancelled Kanye West's visa over 'Heil Hitler' song – Reuters

    1. Australia says it cancelled Kanye West’s visa over ‘Heil Hitler’ song  Reuters
    2. Minister reveals Kanye West was denied entry to Australia after releasing antisemitic song  Australian Broadcasting Corporation
    3. ‘We don’t need that’: US rapper Kanye West barred from visiting Australia  The Canberra Times
    4. US rapper Kanye West’s Australian visa cancelled  The Mercury
    5. Kanye West barred from Australia over anti-Semitic song  The Nightly

    Continue Reading

  • Global Hydrogen Mobility Alliance: Air Liquide joins a strategic partnership in Europe

    Global Hydrogen Mobility Alliance: Air Liquide joins a strategic partnership in Europe

    Air Liquide has joined the newly launched Global Hydrogen Mobility Alliance, a coalition of industry leaders gathering equipment manufacturers, Automotive & Technology suppliers, Energy & Chemicals players. The Alliance is calling for the acceleration of the development of hydrogen mobility to secure Europe’s industrial strength and sustainability. To better understand this initiative, Erwin Penfornis, Vice President of Air Liquide’s Hydrogen Energy business line, answers our questions.

    What does hydrogen mobility offer that electric batteries do not?

    It adds crucial layers of resilience, competitiveness, and system-wide efficiency. Firstly, it requires much less infrastructure investments. Secondly, the full electrification of Europe’s fleet, especially heavy-duty vehicles, would overwhelm grids, so hydrogen storage can help maintain their stability. On top of that, hydrogen can help solve the growing problem of fluctuating renewable power, providing a way to store and use the energy that would otherwise be wasted. Thirdly, hydrogen vehicles provide a range comparable to that of diesel, with fast refueling times (15 minutes for 600+ km range versus 45 minutes for 400 km for battery electric), and lighter weight for increased payload. Thanks to these advantages, hydrogen is crucial for heavy and long-distance transport, which is difficult to decarbonize.

    Why is this technology not broadly adopted yet?

    The technology is ready: it is mature, safe, and reliable. However, for commercial transport operators, whose margins are tight, the Total Cost of Ownership (TCO)1 is the deciding factor. The current price of hydrogen at the pump needs to be optimized, vehicles are still expensive due to a lack of mass production, and the refueling network needs to get denser. Therefore, it is now urgent to bridge this cost gap.

    How does Europe’s progress compare on the global stage?

    Other regions are moving very quickly and decisively. China, for example, is already the world leader in deployment, with more than 28,000 hydrogen trucks and buses on the roads and hundreds of refueling stations in operation as of this year. They have a stated goal of reaching 1 million vehicles by 2030. This isn’t just about catching up; it’s about Europe leveraging its own strengths to lead in a technology that is vital for our industrial future.

    To create that momentum, the Alliance is calling for a “market activation phase.” What does this involve?

    We are calling for a pragmatic and targeted strategy. At the heart of this approach, we advocate for effective public support for the deployment of refueling infrastructure, drawing inspiration from successful programs like the SWiM initiative in the Netherlands. The principle is to simultaneously develop fleets of trucks and the stations that supply them along key corridors. This method reduces investment risks and offers a concrete pathway to meet European objectives. It must be complemented by other incentives, such as road toll exemptions for zero-emission vehicles.

    This pragmatism also applies to technology: we must be technology-neutral and support both fuel cell vehicles and hydrogen combustion engines to accelerate deployment. Finally, on the supply side, while the goal is 100% decarbonized hydrogen, environmental requirements must be introduced progressively to give the entire ecosystem time to adapt.

    What strategic opportunity does the development of a hydrogen economy represent for Europe today?

    The long-term vision is a competitive and self-sustaining hydrogen mobility market that makes our economy stronger while preserving the environment. At Air Liquide, we are already building toward this future, investing across the entire value chain: from large-scale low-carbon hydrogen production, such as our Normand’Hy electrolyzer, to the distribution infrastructure needed to deliver it to end customers, which is the purpose of TEAL Mobility, our joint venture with TotalEnergies.

    We have a unique opportunity to deliver on Europe’s climate commitments and guarantee its energy safety for the future. This path simultaneously strengthens our industrial competitiveness, creating a powerful synergy for progress. We are ready to join forces with public and private partners to make this vision a reality.

    Continue Reading

  • Nothing’s latest flagship smartphone teases smoother performance, a snappier camera and reimagined glyphs

    Nothing’s latest flagship smartphone teases smoother performance, a snappier camera and reimagined glyphs

    It’s time to unholster our best ‘Nothing’ based puns, because the UK-based brand has revealed its latest smartphone.

    The Nothing Phone (3) is the company’s latest iteration of its flagship line, teasing improved performance and usability, plus a few AI surprises, at a competitive price.

    Continue Reading

  • Maternal and gestational factors associated with congenital anomalies among live births: a nationwide population-based study in Brazil from 2012 to 2020 | BMC Pregnancy and Childbirth

    Maternal and gestational factors associated with congenital anomalies among live births: a nationwide population-based study in Brazil from 2012 to 2020 | BMC Pregnancy and Childbirth

    In this population-based study with more than 26 million live births the findings indicated that women belonging to the most vulnerable social group were exposed to a greater burden of factors that increased the likelihood of having a live birth with CA. However, the patterns of risk factors varied according to the group of anomalies. Maternal education was a risk factor only for neural tube defects, while lack of prenatal care and multifetal gestation were associated with greater odds of having a live birth with CA in all groups, except for those with Down syndrome. Advanced maternal age and previous fetal loss were the factors that increased the odds of CA in all groups.

    Distal risk factors, known as socioeconomic factors, have been shown to increase the odds of children born with CA. Black maternal race/skin color and low education (0 to 3 years), increased the odds of CA by 16% and 8%, respectively. Similarly, Anele et al. (2022) reported that a low education level was associated with a 2.08 times higher risk of births affected by CA, mainly in mothers with higher incomes, indicating the impact of low education on the outcome [27]. Regarding black maternal race/skin color, studies carried out in the United States showed that the risk of birth with CA among African Americans varied according to the CA group, with a greater risk for musculoskeletal malformations and a lower risk for cardiac anomalies [28, 29]. Furthermore, in a study carried out in the southern region of Brazil, Trevilato et al. (2022) reported that black women had 20% higher odds of having children with CA than white women [6]. Both factors are related to greater social vulnerability and are consequently associated with low income [30, 31].

    The contribution of socioeconomic vulnerability to CA has different origins, acts indirectly, and encompasses environmental conditions, such as poor nutrition, as well as social and structural conditions, e.g., lack of access to prenatal care [10, 11, 20, 32]. Thus, we observed that not having had any prenatal consultations during pregnancy or having started late has been shown to increase the odds of birth with CA. Trevilato et al. (2022) reported that women with no prenatal visits had 97% greater odds than women with seven or more prenatal visits of having children with congenital anomalies [6]. Prenatal care assistance allows important guidance on modifiable risks in the mother’s lifestyle, such as smoking, alcohol consumption, diabetes control, and exposure to certain teratogens, to be provided at an early stage of pregnancy, reducing the risk of births with CA [11].

    Women in more vulnerable socioeconomic groups can find difficulties accessing prenatal care since women with lower incomes face barriers such as difficulty covering the cost of services, long waiting times, and difficulties obtaining transportation to reach appointment locations, which can lead to negative attitudes toward health care [33, 34]. Furthermore, Dingemann et al. (2019) reported that women with low education attend fewer prenatal consultations, in addition to having a greater chance of future complications in their children with CA [35]. The absence of prenatal consultations may be related to extreme socioeconomic vulnerability [36, 37]. Furthermore, it was observed that in Brazil, among women who underwent prenatal care, the largest proportion underwent (at least once) an ultrasound (99.7%). However, many congenital anomalies require other complementary exams for accurate diagnosis, which are often not available free of charge for the poorest population [38,39,40].

    Neural tube defects were strongly associated with not having any prenatal consultations during pregnancy and low maternal education. Mothers exposed to these factors may not correctly supplement folic acid in the diet during the critical period of pregnancy in which neural tube development occurs (up to the fourth week of gestation) [27, 41]. It is recommended that supplementation begin as early as possible; ideally, supplementation should be started before pregnancy during conception planning, to reduce the likelihood of birth with neural tube defects [42]. Cui et al. (2021) reported that women with less education and who had unplanned pregnancies had less knowledge about folic acid and had higher odds of not starting to use it before becoming pregnant [43].

    Additionally, there were significant variations in the odds of children being born with CA between regions of the country and CA groups. The leading cause of this variation is underreporting, and the Southeast is the region that best reports births with CA compared to others [7]. The greater chance of mothers living in the Northeast Region having children with neural tube defects has not yet been fully explained. According to a previous study, the Northeast and Southeast regions had the highest prevalence of neural tube defects [44]. The Northeast region of Brazil concentrates almost half of the Brazilian population living in poverty [45], which may help explain the greater odds of residence mothers of having births with neural tube defects, since this condition is highly associated with low income, low education attainment and poor diet (insufficient supplementation) [46, 47]. In addition, the Zika virus epidemic in Brazil in 2014 resulted in an increase in the reporting of live births with microcephaly and other congenital anomalies of the nervous system, especially in the Northeast region [5, 7], which may have contributed to the observed results.

    The odds of having children with cardiac CA also varied widely between regions. Women who lived in the North and Northeast regions were less odds to have children affected by cardiac CA. This result reflects considerable underreporting of this group of CA across regions, which is more pronounced in the country’s poorest regions [7]. A similar result was observed by Salim et al. (2020), who reported fewer cardiac CA notifications in these regions [48]. Early diagnosis of cardiac CA may require a more complex structure than some centers can offer, in addition to trained professionals [49], which leads to underreporting of this group, which is more accentuated in the population and economically vulnerable regions.

    Multifetal pregnancy and fetal loss were also associated with birth with CA. Previous fetal loss can be an indication of previous gestational problems, such as a fetus with severe anomalies. A history of prior anomalies has been shown in other studies to be a risk factor for birth with CA [6, 50], which, therefore, may be related to fetal loss in previous pregnancies. Furthermore, as noted by Al-Dewik et al. (2023), multifetal gestation increased the chances of birth with different types of CA, including cardiac CA and nervous system CA [51], as seen in the present work.

    Maternal biological factors also demonstrated an association with the outcome. Thus, consistent with the literature, advanced maternal age was found to be the factor most strongly associated with the occurrence of births with Down syndrome, as already well known [52]. Additionally, advanced maternal age also elevated the odds of having children born with other CA, such as central nervous system defects and heart defects [52, 53]. The association between advanced maternal age and the risk of chromosomal defects and other CA has been widely recognized, it is seen that the CA risk varies by anomaly type and maternal age. It is worth noting that pregnancies in women under the age of 20 years have also been shown to increase the odds of births with CA, which is primarily attributed to social factors, as early pregnancy may be linked to low income and other lifestyle-related risk factors, such as the use of drugs and alcohol, as previously discussed [54,55,56].

    A relevant aspect of this study was the extensive sample size, as it included all births evaluated nationwide over a long period. Additionally, through the linkage process, it was possible to include live births that were not reported in the SINASC database but were registered in the SIM database. Correcting an information error and substantially enhancing the case group’s size. However, it is important to emphasize that the CA recorded in the SIM were those that were severe enough to result in the individual’s death, which may introduce a bias in this regard. In addition, CA that were not recorded in the SINASC at birth and were not registered in the SIM, were not captured in the notifications and consequently were not included in the analyses. Several factors contribute to this underreporting, including the fact that some CA are not detected at birth because they are not noticeable. In addition, the health team is often not trained to recognize certain more important CA, a capability that varies among Brazilian regions, reinforcing the need for active surveillance of the most important defects [17, 57]. Furthermore, there was no information available on the use of folic acid during pregnancy, which made a more detailed analysis in this regard impossible.

    In summary, this study showed that socioeconomically vulnerable women have an increased odds of having a pregnancy affected by CA, mainly for neural tube defects, due to the sum of the risk factors to which they are exposed. Maternal characteristics such as low education, region of residence, race/black skin color, and late start of prenatal care were associated with the outcome. Biological characteristics, such as advanced maternal age and multifetal gestation, were also shown to be strongly associated with birth with CA. Advanced maternal age had a strong association with birth with Down syndrome, whereas multifetal gestation was mainly associated with neural tube defects. Thus, although many CA are not preventable, primary care measures to reduce associated factors greatly impact preventing births with CA [58, 59]. As noted in this study, there is a great need to identify the factors associated with CA and outcomes at the population level, thereby supporting the establishment of effective public policies that can effectively reduce the incidence of preventable CA, as a broad-coverage support for families wishing to become pregnant, including genetic counseling for families with a history of congenital anomalies in the family, control of maternal infections before conception, nutritional support and folic acid supplementation before conception also, among others, in addition to health actions to monitor and care of those born and living with CA.

    Continue Reading

  • Chemotherapy Linked to DNA Damage in Healthy Cells

    Chemotherapy Linked to DNA Damage in Healthy Cells

    For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues.

    Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed blood cell genomes from 23 patients of all ages who had been treated with a range of chemotherapies.

    Published today (1 July 2025) in Nature Genetics, the researchers show that many but not all chemotherapy agents cause mutations and premature aging in healthy blood.

    As part of Cancer Grand Challenges team Mutographs, the researchers uncovered new patterns of DNA damage, or mutational signatures, associated with specific chemotherapy drugs.

    The researchers suggest that the damaging genetic effects of chemotherapy identified by whole genome sequencing could guide the future treatment of patients with effective chemotherapies that have less harmful effects on healthy tissues.

    Chemotherapy is a type of anti-cancer treatment that works by killing cancer cells. It is a systemic treatment, meaning it works throughout the body, and can be administered as a single chemotherapy drug or a combination of drugs. In developed countries, it is estimated that around 10 per cent of the population has received chemotherapy treatments for cancer and other diseases at some point in their lifetime.

    Chemotherapy can have long-term side effects on healthy, non-cancerous tissues, and is associated with an increased risk of secondary cancers. However, there is limited understanding of the biological mechanisms underlying these side effects.

    With new genomic technologies, researchers can explore mutations in normal cells and begin to investigate the extent and long-term consequences of DNA damage from chemotherapy on healthy tissues.

    In a new study, scientists set out to research the effects of chemotherapy on healthy blood. The Mutographs team at the Sanger Institute, University of Cambridge, CUH and their collaborators chose to study blood due to its ease in sampling and ability to culture blood in the laboratory. Plus, the numbers of mutations in normal blood are very consistent between people, giving a good baseline to see whether they are higher in individuals who have received chemotherapy.

    The researchers sequenced blood cell genomes from 23 individuals aged three to 80 years, who had been treated with a range of chemotherapies for various blood and solid cancers. Most of the patients were treated at Addenbrooke’s Hospital in Cambridge and had received a combination of chemotherapy drugs. Collectively, they had been exposed to 21 drugs from all of the main chemotherapy classes, including alkylating agents, platinum agents and anti-metabolites. The results were compared with genomic data from nine healthy people who had never received chemotherapy.

    From analyzing the whole genome sequence data, the team found that many classes of chemotherapeutics, but not all, do produce higher numbers of mutations in normal blood cells. For example, a three-year-old patient who was treated for neuroblastoma, a cancer of nerve tissue, had more than the number of mutations found in 80-year-olds who had never received chemotherapy.

    By looking at patterns of damage in the DNA, known as mutational signatures, the researchers showed that different chemotherapeutics have different mutational signatures, and identified four new signatures found in chemotherapy-treated patients.

    For instance, the researchers found that some platinum agents, such as carboplatin and cisplatin, caused very high numbers of mutations. Whereas other drugs in the same class, such as oxaliplatin, did not.

    The researchers suggest that if these drugs are used interchangeably in cancer treatment, and assuming they have the same effectiveness, then this sort of genetic information could be incorporated in order to administer chemotherapies with fewer harmful effects.

    The team also made discoveries around the effects of chemotherapy on the population of cells that generate blood, known as hematopoietic stem cells.

    In normal aging, the hematopoietic stem cells producing blood decrease in diversity, due to the expansion of clones of cells that have “driver” mutations in cancer genes. Chemotherapy caused a similar pattern of change, but prematurely in some middle-aged adults. Particularly in children who have had chemotherapy, their blood appeared to prematurely age, which may increase the risk of secondary cancer later in life.

    Scientists suggest that genomic data could help in choosing the chemotherapies for children that minimise this premature aging, and genomic technologies could monitor for further changes later in life.

    “For the first time, we have taken a systematic view of the genetic effects of chemotherapy on healthy tissues – in this case, blood. We find that some, but not all chemotherapies cause genetic mutations and premature ageing in normal blood. This study lays the groundwork for future research into the effects of chemotherapy on many other normal tissues, including multiple tissue sampling pre and post treatment, across a range of chemotherapies in a larger group of patients. This comprehensive view would reveal the full range of effects of different chemotherapies, and help us to optimise patient health in the long term.”

    Dr Emily Mitchell, first author at the Wellcome Sanger Institute and clinician at CUH

    “The effects of chemotherapy we see here – increasing numbers of mutations and premature ageing of healthy blood – reasonably contribute to the heightened risk of additional cancers and the patient’s ability to tolerate further treatments in the future. Given that for many cancers, chemotherapy drugs can be switched with other agents to achieve similar results, we hope such genomic data will guide the optimisation of future treatment plans to deliver effective chemotherapies with much fewer damaging side effects for patients.”

    Dr Jyoti Nangalia, co-lead author at the Wellcome Sanger Institute and Consultant Haematologist at CUH

    “This important research helps us better understand how some chemotherapy drugs can affect healthy cells as well as cancer cells. While many cancers can now be targeted using precision therapies, chemotherapy remains a key way to treat some cancers and saves many lives every year, so it’s vital that patients continue with the treatment recommended by their doctor. At the same time, studies like this are crucial for helping scientists improve cancer treatments in the future – making them not only more effective but also safer for people living with cancer.”

    David Scott, Director of Cancer Grand Challenges

    “I believe that the results of this study hold implications for the way that chemotherapies are used to treat cancer patients. We are constantly on the lookout for better ways of giving therapy and minimising the side effects of toxic, systemic treatments. I’m hopeful that the genomic information from this and future studies will guide choices of chemotherapies, and their adoption in clinical practice.”

    Professor Sir Mike Stratton, Mutographs team lead and co-lead author at the Wellcome Sanger Institute

    Reference: Mitchell E, Pham MH, Clay A, et al. The long-term effects of chemotherapy on normal blood cells. Nat Genet. 2025:1-11. doi: 10.1038/s41588-025-02234-x

    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

    Continue Reading

  • No negligence to be tolerated in achieving economic targets: PM – RADIO PAKISTAN

    1. No negligence to be tolerated in achieving economic targets: PM  RADIO PAKISTAN
    2. PM Shehbaz Sharif applauds FBR’s record tax revenue growth for FY 2024-25  Ptv.com.pk
    3. Pakistan PM orders wider POS rollout after $3 billion tax surge to sustain reform momentum  Arab News
    4. PM Shehbaz Sharif reviews FBR reforms, lauds 42% revenue surge  nation.com.pk
    5. PM Shehbaz applauds record 42% tax revenue surge, directs swift implementation of economic reforms  Associated Press of Pakistan

    Continue Reading

  • MRI Technique Detects Brain Disease by Mapping Metabolism

    MRI Technique Detects Brain Disease by Mapping Metabolism


    Register for free to listen to this article

    Thank you. Listen to this article using the player above.


    Want to listen to this article for FREE?


    Complete the form below to unlock access to ALL audio articles.

    A new technology that uses clinical MRI machines to image metabolic activity in the brain could give researchers and clinicians unique insight into brain function and disease, researchers at the University of Illinois Urbana-Champaign report. The non-invasive, high-resolution metabolic imaging of the whole brain revealed differences in metabolic activity and neurotransmitter levels among brain regions; found metabolic alterations in brain tumors; and mapped and characterized multiple sclerosis lesions — with patients only spending minutes in an MRI scanner.

    Led by Zhi-Pei Liang, a professor of electrical and computer engineering and a member of the Beckman Institute for Advanced Science and Technology at the U. of I., the team reported its findings in the journal Nature Biomedical Engineering.

    “Understanding the brain, how it works and what goes wrong when it is injured or diseased is considered one of the most exciting and challenging scientific endeavors of our time,” Liang said. “MRI has played major roles in unlocking the mysteries of the brain over the past four decades. Our new technology adds another dimension to MRI’s capability for brain imaging: visualization of brain metabolism and detection of metabolic alterations associated with brain diseases.”

    Conventional MRI provides high-resolution, detailed imaging of brain structures. Functional MRI maps brain activity by detecting changes in blood flow and blood oxygenation level, which are closely linked to neural activity. However, they cannot provide information on the metabolic activity in the brain, which is important for understanding function and disease, said postdoctoral researcher Yibo Zhao, the first author of the paper.

    “Metabolic and physiological changes often occur before structural and functional abnormalities are visible on conventional MRI and fMRI images,” Zhao said. “Metabolic imaging, therefore, can lead to early diagnosis and intervention of brain diseases.”

    Both MRI and fMRI techniques are based on magnetic resonance signals from water molecules. The new technology measures signals from brain metabolites and neurotransmitters as well as water molecules, a technique known as magnetic resonance spectroscopic imaging. These MRSI images can provide significant new insights into brain function and disease processes, and could improve sensitivity and specificity for the detection and diagnosis of brain diseases, Zhao said.

    Other attempts at MRSI have been bogged down by the lengthy times required to capture the images and high levels of noise obscuring the signals from neurotransmitters. The new technique addresses both challenges.

    “Our technology overcomes several long-standing technical barriers to fast high-resolution metabolic imaging by synergistically integrating ultrafast data acquisition with physics-based machine learning methods for data processing,” Liang said. With the new MRSI technology, the Illinois team cut the time required for a whole brain scan to 12 and a half minutes.

    The researchers tested their MRSI technique on several populations. In healthy subjects, the researchers found and mapped varying metabolic and neurotransmitter activity across different brain regions, indicating that such activity is not universal. In patients with brain tumors, the researchers found metabolic alterations, such as elevated choline and lactate, in tumors of different grades — even when the tumors appeared identical on clinical MRI images. In subjects with multiple sclerosis, the technique detected molecular changes associated with neuroinflammatory response and reduced neuronal activity up to 70 days before changes become visible on clinical MRI images, the researchers report.

    The researchers foresee potential for broad clinical use of their technique: By tracking metabolic changes over time, clinicians can assess the effectiveness of treatments for neurological conditions, Liang said. Metabolic information also can be used to tailor treatments to individual patients based on their unique metabolic profiles.

    “High-resolution whole-brain metabolic imaging has significant clinical potential,” said Liang, who began his career in the lab of the late Illinois professor Paul Lauterbur, recipient of the Nobel Prize for developing MRI technology. “Paul envisioned this exciting possibility and the general approach, but it has been very difficult to achieve his dream of fast high-resolution metabolic imaging in the clinical setting.

    “As healthcare is moving towards personalized, predictive and precision medicine, this high-speed, high-resolution technology can provide a timely and effective tool to address an urgent unmet need for noninvasive metabolic imaging in clinical applications.”

    Reference: Zhao Y, Li Y, Jin W, et al. Ultrafast J-resolved magnetic resonance spectroscopic imaging for high-resolution metabolic brain imaging. Nat Biomed Eng. 2025. doi: 10.1038/s41551-025-01418-4

    This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.

    Continue Reading